# Docetaxel and Sirolimus in Patients With Advanced Malignancies

> **NCT01054313** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 103 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Docetaxel (Taxotere)
- **DRUG:** Sirolimus (Rapamycin)
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01054313
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01054313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01054313, "Docetaxel and Sirolimus in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01054313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*